Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Structure and function of the blood–brain barrier

Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185 · see citing works

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works

A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain

Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,138 · see citing works

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631 · see citing works

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,479 · see citing works

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

Andrews, D. W., Scott, C., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner‐Wasik, M., Demas, W. F., Ryu, J. K., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,418 · see citing works

Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases

Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,212 · see citing works

Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF

Holash, J. A., Maisonpierre, P. C., Compton, D. L., Boland, P., Alexander, C., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,181 · see citing works

Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

Köcher, M., Soffietti, R., Abacıoğlu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R., Carrié, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988 · see citing works

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425 · see citing works

Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery

Vecht, C. J., Haaxma-Reiche, H., Noordijk, E. M., Padberg, G. W., Voormolen, J. H. C., Hoekstra, F. H., Tans, J. T. J., Lambooy, N., Metsaars, J. A. L., Wattendorff, A. R., et al. (1993) · Annals of Neurology · doi:10.1002/ana.410330605 · Cited by 1,050 · see citing works

Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial

Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., Choucair, A. K., Fox, S., Suh, J. H., Roberge, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not114 · Cited by 964 · see citing works

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 930 · see citing works

Distribution of Brain Metastases

Delattre, J., Krol, G. S., Thaler, H. T., et al. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520310047016 · Cited by 785 · see citing works

Methotrexate: Distribution in Cerebrospinal Fluid after Intravenous, Ventricular and Lumbar Injections

Shapiro, W. R., Young, D. F., & Mehta, B. M. (1975) · New England Journal of Medicine · doi:10.1056/nejm197507242930402 · Cited by 686 · see citing works

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638 · see citing works

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Costa, D. B., Kobayashi, S. S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 601 · see citing works

Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy

Koppelmans, V., Breteler, M. M. B., Boogerd, W. J., Seynaeve, C., Gundy, C. M., & Schagen, S. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.0189 · Cited by 551 · see citing works

Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve

Ahles, T. A., Saykin, A. J., McDonald, B. C., Li, Y., Furstenberg, C. T., Hanscom, B. S., Mulrooney, T. J., Schwartz, G. N., & Kaufman, P. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0827 · Cited by 536 · see citing works

Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients

Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F. J., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 521 · see citing works

Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development

Ohtsuki, S., & Terasaki, T. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9374-5 · Cited by 456 · see citing works

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases

Tsao, M. N., Lloyd, N. S., Wong, R. K. S., Chow, E., Rakovitch, E., Laperrière, N., Xu, W., & Sahgal, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003869.pub3 · Cited by 434 · see citing works

The seed and soil hypothesis: vascularisation and brain metastases

Fidler, I. J., Yano, S., Zhang, R.-D., Fujimaki, T., & Bucana, C. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00622-2 · Cited by 432 · see citing works

CNS complications of radiotherapy and chemotherapy

Soussain, C., Ricard, D., Fike, J. R., Mazeron, J., Psimaras, D., & Delattre, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61299-x · Cited by 407 · see citing works

Why avoid the hippocampus? A comprehensive review

Gondi, V., Tomé, W. A., & Mehta, M. P. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.09.013 · Cited by 397 · see citing works

Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen

Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A. (2004) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390490510905 · Cited by 397 · see citing works

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

Welsh, J. W., Komaki, R., Amini, A., Munsell, M. F., Unger, W., Allen, P. K., Chang, J. Y., Wefel, J. S., McGovern, S. L., Garland, L. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1174 · Cited by 395 · see citing works

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370 · see citing works

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · see citing works

Phase II Randomized Trial of Temozolomide and Concurrent Radiotherapy in Patients With Brain Metastases

Antonadou, D., Paraskevaidis, M., Sarris, G., Coliarakis, N., Economou, I., Karageorgis, P., & Throuvalas, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.140 · Cited by 331 · see citing works

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation

Park, S. J., Kim, H. T., Lee, D., Kim, K. P., Kim, S.-W., Suh, C. H., & Lee, J. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.092 · Cited by 323 · see citing works

Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation

Porta, R., Sánchez-Torres, J. M., Paz-Ares, L., Massutí, B., Reguart, N., Mayo, C., Lianes, P., Queralt, C., Guillem, V., Salinas, P., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00195609 · Cited by 316 · see citing works

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314 · see citing works

Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer

de Ruiter, M. B., Reneman, L., Boogerd, W. J., Veltman, D. J., van Dam, F. S. A. M., Nederveen, A. J., Boven, E., & Schagen, S. B. (2010) · Human Brain Mapping · doi:10.1002/hbm.21102 · Cited by 306 · see citing works

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282 · see citing works

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320

Sperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R., Souhami, L., Buyyounouski, M. K., Khuntia, D., Demas, W., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.11.042 · Cited by 274 · see citing works

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1

Robinet, G., Thomas, P. A., Breton, J.-L., Léna, H., Gouva, S., Dabouis, G., Bennouna, J., Souquet, P. J., Balmès, P., Thiberville, L., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008338312647 · Cited by 266 · see citing works

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

Eichler, A. F., Kahle, K. T., Wang, D. L., Joshi, V. A., Willers, H., Engelman, J. A., Lynch, T. J., & Sequist, L. V. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq076 · Cited by 265 · see citing works

Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data

Davis, F. G., Dolecek, T. A., McCarthy, B. J., & Villano, J. L. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos152 · Cited by 258 · see citing works

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma

Iuchi, T., Shingyoji, M., Sakaida, T., Hatano, K., Nagano, O., Itakura, M., Kageyama, H., Yokoi, S., Hasegawa, Y., Kawasaki, K., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.016 · Cited by 257 · see citing works

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)

Barlési, F., Gervais, R., Léna, H., Hureaux, J., Berard, H., Paillotin, D., Bota, S., Monnet, I., Chajara, A., & Robinet, G. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr003 · Cited by 243 · see citing works

Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

Socinski, M. A., Langer, C. J., Huang, J. E., Kolb, M. M., Compton, P. G., Wang, L. E., & Akerley, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0616 · Cited by 240 · see citing works

A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases

Abrey, L. E., Olson, J. D., Raizer, J. J., et al. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012226718323 · Cited by 231 · see citing works

Brain metastases admissions in Sweden between 1987 and 2006

Smedby, K. E. E., Brandt, L., Bäcklund, L. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605373 · Cited by 230 · see citing works

Dietary factors and the survival of women with breast carcinoma

Holmes, M. D., Stampfer, M. J., Colditz, G. A., ROSNER, B. A., Hunter, D. J., & Willett, W. C. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990901)86:5 · Cited by 218 · see citing works

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

Kim, J.-E., Lee, K. H., Choi, Y., Yoon, D. H., Kim, S.-W., Suh, C., & Lee, J. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.12.011 · Cited by 218 · see citing works

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214 · see citing works

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial

Verger, E., Gil‐Gil, M., Yayá, R., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.04.061 · Cited by 211 · see citing works

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment

Tallet, A. R., Azria, D., Barlési, F., Spano, J., Carpentier, A. F., Gonçalves, A., & Métellus, P. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-77 · Cited by 209 · see citing works

Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933

Gondi, V., Tomé, W. A., Marsh, J. C., Struck, A. F., Ghia, A. J., Turian, J. V., Bentzen, S. M., Kuo, J. S., Khuntia, D., & Mehta, M. P. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.02.030 · Cited by 182 · see citing works

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

Christodoulou, C., Bafaloukos, D. I., Kosmidis, P., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008354323167 · Cited by 175 · see citing works

Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)

Sperduto, P. W., Shanley, R., Luo, X., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.002 · Cited by 172 · see citing works

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 161 · see citing works

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Sun, M., Behrens, C., Feng, L., Ozburn, N. C., Tang, X., Yin, G., Komaki, R. U., Varella‐Garcia, M., Hong, W. K., Aldape, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2921 · Cited by 152 · see citing works

Gefitinib in Patients with Brain Metastases from Non–Small-Cell Lung Cancer: Review of 15 Clinical Cases

Namba, Y., Kijima, T., Yokota, S., et al. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.026 · Cited by 138 · see citing works

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Camidge, D. R., Bang, Y., Kwak, E. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2501 · Cited by 135 · see citing works

First-Line Chemotherapy with Vinorelbine, Gemcitabine, and Carboplatin in the Treatment of Brain Metastases from Non-Small-Cell Lung Cancer: A Phase II Study

Bernardo, G. D., Cuzzoni, Q., Strada, M. R., et al. (2002) · Cancer Investigation · doi:10.1081/cnv-120001173 · Cited by 134 · see citing works

Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer

Cortés, J., Rodríguez, J., Aramendía, J. M., et al. (2002) · Oncology · doi:10.1159/000066520 · Cited by 128 · see citing works

Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

Lee, E., Keam, B., Kim, D., Kim, T. M., Lee, S., Chung, D. H., & Heo, D. S. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318294c8e8 · Cited by 121 · see citing works

Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer

Bearz, A., Garassino, I. M. G., Tiseo, M., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.018 · Cited by 120 · see citing works

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

Cappuzzo, F., Ardizzoni, A., Parra, H. J. S., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00189-2 · Cited by 117 · see citing works

Whole-Brain Radiotherapy With Simultaneous Integrated Boost to Multiple Brain Metastases Using Volumetric Modulated Arc Therapy

Lagerwaard, F. J., van der Hoorn, E. A. P., Verbakel, W. F. A. R., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.029 · Cited by 109 · see citing works

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases

Dziadziuszko, R., Ardizzoni, A., Postmus, P. E., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00234-x · Cited by 108 · see citing works

A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer

Neuhaus, T., Ko, Y., Müller, R.-P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604835 · Cited by 101 · see citing works

Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first

Lee, D. H., Han, J., Kim, H. T., Yoon, S. J., Pyo, H. R., Cho, K. H., Shin, S., Yoo, H., Lee, S. H., & Lee, J. S. (2008) · Cancer · doi:10.1002/cncr.23526 · Cited by 101 · see citing works

A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung

Guerrieri, M., Wong, K., Ryan, G. F., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.02.019 · Cited by 100 · see citing works

Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma

Bailon, O., Chouahnia, K., Augier, A., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos004 · Cited by 95 · see citing works

Whole Brain Irradiation With Hippocampal Sparing and Dose Escalation on Multiple Brain Metastases: A Planning Study on Treatment Concepts

Prokić, V., Wiedenmann, N. E., Fels, F., Schmucker, M., Nieder, C., & Grosu, A. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.02.036 · Cited by 82 · see citing works

Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer

Minotti, V., Crinò, L., Meacci, M. L., et al. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00021-x · Cited by 81 · see citing works

Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement

Takeda, M., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c28e7 · Cited by 80 · see citing works

First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

Camidge, D. R., Bazhenova, L. A., Salgia, R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8031 · Cited by 80 · see citing works

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y. H., Ikemi, Y., Sakamori, Y., Mio, T., Katsura, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1691-z · Cited by 79 · see citing works

Combination Chemotherapy of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support in Patients with Brain Metastases from Non-Small Cell Lung Cancer

藤田, 昭., Fukuoka, S., Takabatake, H., et al. (2000) · Oncology · doi:10.1159/000012185 · Cited by 76 · see citing works

Whole-Brain Radiation Therapy Plus Concomitant Temozolomide for the Treatment of Brain Metastases From Non–Small-Cell Lung Cancer: A Randomized, Open-Label Phase II Study

Chua, D. T. T., Krzakowski, M. J., CHOUAID, C., Pallotta, M. G., Martinez, J. I., Gottfried, M., Curran, W. J., & Throuvalas, N. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.022 · Cited by 75 · see citing works

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases

Cortot, A. B., Italiano, A., Burel‐Vandenbos, F., Martel‐Planche, G., & Hainaut, P. L. (2010) · Cancer · doi:10.1002/cncr.25014 · Cited by 64 · see citing works

Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

Shaw, A. T., Mehra, R., Kim, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8010 · Cited by 62 · see citing works

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement

Maillet, D., Martel‐Lafay, I., Arpin, D., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318288dc2d · Cited by 56 · see citing works

Temporal and gender-related trends in brain metastases from lung and breast cancer.

Yawn, B. P., Wollan, P. C., Schroeder, C., et al. (2003) · PubMed · Cited by 56 · see citing works

Effects of tamoxifen on telomerase activity in breast carcinoma cell lines

Aldous, W. K., Marean, A. J., Dehart, M. J., Matej, L. A., & Moore, K. H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990401)85:7 · Cited by 56 · see citing works

Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases

Rodrigues, G., Yartsev, S., Yaremko, B., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.047 · Cited by 53 · see citing works

A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.

Sung, C., Blaney, S. M., Cole, D. E., et al. (1994) · PubMed · Cited by 51 · see citing works

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement–Positive Non–Small-Cell Lung Cancer

Kaneda, H., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182843771 · Cited by 50 · see citing works

Implications for preserving neural stem cells in whole brain radiotherapy and prophylactic cranial irradiation: a review of 2270 metastases in 488 patients

Wan, J., Zhang, S.-J., Wang, L., et al. (2012) · Journal of Radiation Research · doi:10.1093/jrr/rrs085 · Cited by 50 · see citing works

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer

Cotto, C., Bérille, J., Souquet, P. J., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00507-2 · Cited by 44 · see citing works

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up

Ruppert, A.-M., Beau‐Faller, M., Neuville, A., Guérin, É., Voegeli, A.-C., Mennecier, B., Legrain, M., Molard, A., Jeung, M.-Y., Gaub, M.-P., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00162307 · Cited by 44 · see citing works

Treatment of Brain Metastases in Lung Cancer: Strategies to Avoid/Reduce Late Complications of Whole Brain Radiation Therapy

Shaw, M. G., & Ball, D. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0258-0 · Cited by 43 · see citing works

The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis.

Li, Z., Lu, J., Zhao, Y., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.e18065 · Cited by 40 · see citing works

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib

Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Yoshida, H., Yagi, Y., Nakaoku, T., & Mishima, M. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829cebbb · Cited by 39 · see citing works

EGFR , KRAS , BRAF , and HER ‐2 molecular status in brain metastases from 77 NSCLC patients

Villalva, C., Duranton‐Tanneur, V., Guilloteau, K., Burel‐Vandenbos, F., Wager, M., Doyen, J., Levillain, P., Fontaine, D., Blons, H., Pédeutour, F., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.82 · Cited by 38 · see citing works

Lung Cancer with a Single Brain Metastasis: Therapeutic Options

Rizzi, A., Tondini, M., Rocco, G., et al. (1990) · Tumori Journal · doi:10.1177/030089169007600614 · Cited by 31 · see citing works

Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.

Otterson, G. A., Riely, G. J., Shaw, A. T., Crinò, L., Kim, D., Martins, R. G., Salgia, R., Zhou, C., Solomon, B., Wilner, K. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7600 · Cited by 29 · see citing works

A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.

Nakagawa, K., Kiura, K., Nishio, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8033 · Cited by 20 · see citing works

Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report

Dziadziuszko, K., Szurowska, E., Pienkowska, J. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000091 · Cited by 18 · see citing works

Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN).

Besse, B., Moulec, S. L., Senellart, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8059 · Cited by 15 · see citing works

Cerebral penetration of gefitinib in patients with lung adenocarcinoma.

Wang, M., Jing, Z., & Minjiang, C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7608 · Cited by 10 · see citing works

Prognostische Relevanz der Metastasenlokalisation bei nicht kleinzelligem Bronchialkarzinom im Tumorstadium IV – Ergebnisse einer prospektiven epidemiologischen Studie

Blankenburg, T., Gottschlich, B., Schütte, W., et al. (2010) · Pneumologie · doi:10.1055/s-0029-1244238 · Cited by 1 · see citing works

Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole Brain Radiation Therapy (WBRT) Versus WBRT Plus Stereotactic Radiosurgery (SRS) in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)

Sperduto, P. W., Shanley, R., Luo, X., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.06.135 · Cited by 1 · see citing works

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718 · see citing works

Titanium Dioxide Nanoparticles &amp;ndash; Prospects and Applications in Medicine

Ziental, D., Czarczynska-Goslinska, B., Mlynarczyk, D. T., Glowacka-Sobotta, A., Stanisz, B., Goslinski, T., & Sobotta, L. (2020) · doi:10.20944/preprints202002.0271.v1 · Cited by 721 · see citing works

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637 · see citing works

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173 · see citing works

EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

Soon, Y. Y., Leong, C. N., Koh, W. Y., & Tham, I. W. K. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.12.011 · Cited by 110 · see citing works

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer

Su, P.-L., Wu, Y.-L., Chang, W.-Y., Ho, C.-L., Tseng, Y.-L., Lai, W.-W., Su, W.-C., Lin, C.-C., & Yang, S.-C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918797589 · Cited by 49 · see citing works

STUDY ON THE EFFECTS OF RADIOTHERAPY ON T-CELL SUBGROUPS OF THE MALIGNANT TUMOR PATIENTS

Zhao, H. (2000) · Journal of Nantong Medical

A clinical study of 57 patients with natural killer/T-cell lymphoma,nasal type

Wang, R. (2008) · Xinjiang Yike Daxue xuebao

Non-asbestos-related malignant mesothelioma. A review

Peterson, J. T., Greenberg, S. D., & Buffler, P. A. (1984) · Cancer · doi:10.1002/1097-0142(19840901)54:5 · Cited by 251 · see citing works

[Results of radiotherapy in case of Hodgkin's disease after primary failure of chemotherapy and recurrence after chemotherapy ].

Gassmann, W., Schmitz, N., Breidenbach, M., et al. (1982) · PubMed

The Influence of Radiotherapy and Chemotherapy on Platelet Parameters in Tumor Patients and Its Significance

Changju, S. (2008) · The Journal of Medical Theory and Practice